Upadacitinib monotherapy effective in refractory RA
![Research](https://www.ausdoc.com.au/wp-content/uploads/2022/08/dreamstime_xl_39632983-2.jpg)
Monotherapy with the JAK1-selective inhibitor upadacitinib is effective in patients with active rheumatoid arthritis who have an inadequate response to methotrexate, according to results of a phase 3 trial.
Researchers from 24 countries compared upadacitinib monotherapy to continuing methotrexate treatment in a randomised controlled trial of 648 rheumatoid arthritis patients with an inadequate response to methotrexate.